These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8726036)

  • 41. Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1992; 38(1):7-13. PubMed ID: 1618006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults.
    Phillips H; Van Hook CJ; Butler T; Todd WM
    Chest; 1993 Nov; 104(5):1387-92. PubMed ID: 8222793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
    Dan M; Poch F; Edelman A; Asherov J; Hafely H; Atzmon Y
    J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-vitro activity of a combination of two oral beta-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.
    Johnson DM; Jones RN
    J Antimicrob Chemother; 1998 Oct; 42(4):555-7. PubMed ID: 9818764
    [No Abstract]   [Full Text] [Related]  

  • 49. [In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae].
    Kawada H; Kitayama A; Fukuoka T; Ishii C; Abe T; Kakuta M; Domon H; Ohya S; Utsui Y
    Jpn J Antibiot; 1999 Aug; 52(8):533-40. PubMed ID: 10587878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; González N; Echeverría O; Torrico M; Martín JE; Valdés L; Prieto J
    J Chemother; 2007 Dec; 19(6):670-2. PubMed ID: 18230548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antibacterial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections (II)].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1994 Dec; 47(12):1753-61. PubMed ID: 7877255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
    Jones RN; Biedenbach DJ; Croco MA; Barrett MS
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):573-8. PubMed ID: 9764398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of RO 15-8074 and RO 19-5247.
    Valle T; Jalanko E; Scheinin L; Renkonen OV
    Eur J Clin Microbiol; 1987 Apr; 6(2):167-9. PubMed ID: 3109897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.